Telehealth ADHD Prescribing: What PMHNPs Can Do in Pennsylvania

You’ve built a solid practice managing depression and anxiety via telehealth. Now patients are asking: ‘Can you help with my ADHD too?’

It’s a fair question. Adult ADHD diagnoses surged during the pandemic — stimulant prescriptions jumped by millions between 2020-2022 as people finally accessed care remotely. But here’s the problem: prescribing Adderall or Vyvanse through a screen isn’t the same as managing an SSRI. You’re dealing with Schedule II controlled substances, DEA waivers that keep getting extended at the last minute, and state laws that can differ wildly depending on whether you’re an MD or a PMHNP.

Let’s cut through the noise. This guide walks through exactly what psychiatrists and psychiatric nurse practitioners can legally do for ADHD medication management via telehealth in 2026 — focusing on the six states where most providers work: California, Texas, Florida, New York, Pennsylvania, and Illinois.

The Federal Framework: Where Things Stand Right Now

The Ryan Haight Act baseline: Before COVID, federal law required at least one in-person exam before prescribing Schedule II drugs (like Adderall, Ritalin, Vyvanse) via telemedicine. That’s the Ryan Haight Act of 2008, designed to prevent online pill mills.

COVID changed everything: The DEA waived that in-person requirement during the Public Health Emergency, letting providers initiate stimulant prescriptions through video visits. That flexibility was supposed to end multiple times — but keeps getting extended. Most recently, the DEA and HHS pushed the deadline through December 31, 2025.

What happens in 2026? As of February 2026, we’re in limbo. The waiver expired, but enforcement hasn’t kicked in yet. Congress is debating permanent telehealth prescribing rules for controlled substances, the DEA floated (but hasn’t finalized) a ‘special registration’ pathway for telemedicine prescribers, and state-by-state confusion reigns.

Bottom line for now: You can still prescribe ADHD medications via telehealth to new patients under the extended federal allowance, but you need a backup plan. That might mean:

• Partnering with local clinics for in-person exams if federal rules revert
• Using non-stimulant alternatives (atomoxetine, bupropion) that aren’t Schedule II
• Focusing on established patients you’ve seen in person before

The regulatory uncertainty is real. But demand for ADHD care through telehealth isn’t going anywhere — which is why understanding your state’s specific rules matters even more than federal policy right now.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrists vs PMHNPs: The Authority Gap That Actually Matters

Here’s what nobody tells you upfront: your license type determines what ADHD care you can provide in most states.

Psychiatrists (MD/DO): Full Authority Everywhere

If you’re a psychiatrist, you have unrestricted prescriptive authority in every state. No supervision required. No quantity limits. No special protocols. You can:

• Diagnose ADHD via comprehensive video evaluation
• Initiate stimulant treatment on day one
• Write 30-day prescriptions (or 90-day supplies with sequential scripts per DEA rules)
• Manage all aspects of medication without consulting anyone

The only constraints are federal DEA rules and standard-of-care documentation. That’s it.

PMHNPs: It Depends Where You Practice

Nurse practitioners? Your scope varies dramatically by state:

Full Practice States (after experience):

• New York: After 3,600 supervised hours (~2 years), you can prescribe stimulants independently with no MD oversight
• Illinois: After 4,000 hours + additional training, full prescriptive authority including Schedule II drugs
• California: Transitioning to independence via AB 890 — experienced NPs (3+ years) can apply for ‘104 NP’ status and practice autonomously

Restricted States:

• Texas: NPs cannot prescribe Schedule II drugs to outpatients period. Only MDs can write Adderall prescriptions outside hospital/hospice settings. You need a collaborating psychiatrist to manage ADHD stimulant therapy.
• Florida: NPs require physician supervision AND can only prescribe 7-day supplies of Schedule II drugs — unless you’re a certified ‘psychiatric nurse’ working under a psychiatrist’s protocol, then you can write 30-day prescriptions
• Pennsylvania: NPs can only prescribe 72 hours of Schedule II medication initially, must notify supervising physician, then limited to 30-day supplies with ongoing physician involvement

The economic reality: In restricted states, psychiatrists are essentially the bottleneck. You can’t scale ADHD services with NPs alone — the MD has to be in the loop for every stimulant prescription. That matters if you’re thinking about caseload capacity or joining a platform that promises ‘unlimited patient volume.’

State-by-State Breakdown: What You Need to Know Before Treating ADHD Patients

California: Progressive Rules, Competitive Market

Who can prescribe:

• Psychiatrists: Full authority, no restrictions
• PMHNPs: Need physician supervision unless you have 3+ years experience and ‘104 NP’ certification. Even supervised NPs can prescribe Schedule II with proper pharmacology training and protocols.

Telehealth prescribing: California follows federal rules — no additional state barriers. Telehealth parity is mandated by law (AB 744), so insurance reimbursement equals in-person rates.

Key requirement: All prescriptions, including controlled substances, must be e-prescribed. Paper scripts aren’t an option anymore.

Market conditions:

• Psychiatrist density: ~1 per 5,000 residents (average), but huge gaps in Central Valley and rural areas
• High demand especially in tech-heavy areas where adult ADHD awareness is strong
• Competitive urban markets (SF, LA) balanced by underserved rural/suburban communities
• Strong insurance coverage (Covered California, Medi-Cal expansion) means most patients have some coverage

Watch out for: The Medical Board increased scrutiny of teleprescribing after some high-profile cases of inappropriate stimulant prescribing. Document thoroughly, use rating scales, get collateral information when possible.

Texas: Strict Oversight, Severe Shortages

Who can prescribe:

• Psychiatrists: Full authority
• PMHNPs: Cannot prescribe Schedule II controlled substances to outpatients. Period. You can manage everything else about ADHD care (therapy, non-stimulants), but an MD must write the Adderall prescription.

Telehealth prescribing: Texas explicitly allows telehealth prescribing of controlled substances for mental health treatment — but NOT for chronic pain management. Since ADHD isn’t pain management, psychiatrists can prescribe stimulants via video visit. Must be synchronous video (audio-only doesn’t count for controlled substances).

Collaborative agreements: NPs need a supervising physician. One MD can oversee up to 7 NPs maximum. The agreement typically states the NP will NOT prescribe Schedule II drugs, and the physician handles those.

Market conditions:

• Psychiatrist density: ~1 per 9,000 residents (rank 43rd nationally — one of the worst shortages)
• 185 of 254 counties are designated Mental Health Professional Shortage Areas
• Massive rural access gaps, high demand for telepsychiatry
• Mixed payor base (high uninsured/self-pay population, but growing Medicaid and employer coverage)

The opportunity: If you’re a Texas-licensed psychiatrist, you’re in demand. The state desperately needs prescribers who can manage ADHD medications. But expect regulatory vigilance — Texas legislators have been concerned about telehealth companies over-prescribing stimulants with minimal oversight.

Florida: Permissive Telehealth Law, Complex NP Rules

Who can prescribe:

• Psychiatrists: Full authority
• PMHNPs: Must have physician protocol. Standard NP limit is 7-day supply for Schedule II drugs, BUT ‘psychiatric nurses’ (PMHNPs working under psychiatrist supervision) are exempt from this limit when prescribing for mental health conditions. So you can write 30-day prescriptions if properly credentialed and supervised.

Telehealth prescribing: Florida statute 456.47 explicitly permits teleprescribing Schedule II drugs for psychiatric disorders (ADHD qualifies). This is actually one of the more permissive state laws — Florida carved out mental health treatment from its general restrictions on remote controlled substance prescribing.

Key requirements:

• Must use EFORCSE (state prescription monitoring program) before prescribing controlled substances
• E-prescribing mandated for controlled substances
• Collaborative protocol for NPs must be with a psychiatrist (not just any physician)

Market conditions:

• Psychiatrist density: ~1 per 8,577 residents (rank 42nd — significant shortage)
• South Florida has better provider coverage; North Florida and interior regions severely underserved
• Large pediatric and young adult population
• Growing demand for adult ADHD services

Watch out for: Florida’s Board of Medicine actively disciplines inappropriate controlled substance prescribing. Standard-of-care documentation is essential — comprehensive evaluations, follow-up protocols, monitoring for diversion risk.

New York: NP Independence After Experience

Who can prescribe:

• Psychiatrists: Full authority
• PMHNPs: After completing 3,600 hours of supervised practice (~2 years), you can practice completely independently including prescribing any controlled substances. During the initial period, you need a written collaborative agreement with a physician but can still prescribe stimulants if it’s in the agreement.

Telehealth prescribing: No state restrictions beyond federal law. New York has strong telehealth parity — both Medicaid and private insurers cover telepsychiatry at equal rates.

Key requirements:

• Mandatory e-prescribing for all prescriptions since 2016
• Must check I-STOP (state prescription monitoring program) before EVERY controlled substance prescription — this is strictly enforced

Market conditions:

• Psychiatrist density: ~1 per 2,900 residents (rank 4th — one of the best in the country)
• Concentration in NYC metro; upstate rural areas still have shortages
• Competitive urban market, but huge patient volume and high ADHD awareness
• Strong insurance coverage and payment rates

The advantage: New York’s progressive scope of practice rules mean experienced PMHNPs can run independent ADHD practices after their supervised period. For MDs, the competitive environment is offset by massive patient demand and solid reimbursement.

Pennsylvania: Restrictive NP Rules, Moderate Supply

Who can prescribe:

• Psychiatrists: Full authority
• PMHNPs: Must have collaborative agreement with physician. Can only prescribe 72 hours of Schedule II medication initially and must notify supervising physician. Ongoing therapy limited to 30-day supplies. Physician must be involved before extending beyond initial prescription.

Telehealth prescribing: No Pennsylvania-specific restrictions on controlled substances via telehealth. The state medical board has endorsed telemedicine as meeting standard of care when done properly.

Collaborative agreements: Must be filed with Board of Nursing. One physician can collaborate with up to 4 NPs. The agreement must specify which drugs the NP can prescribe and under what conditions.

Market conditions:

• Psychiatrist density: ~1 per 4,586 residents (slightly better than national average)
• Good coverage in Philadelphia and Pittsburgh; rural central/northern PA underserved
• Strong telehealth adoption, payment parity through regulator directives
• Many patients wait months for appointments outside metro areas

Practical workflow: The 72-hour initial limit creates extra steps. Common approach: NP does evaluation, MD writes first stimulant prescription (or NP gives 3-day supply), then NP manages follow-up with 30-day refills. Requires team coordination.

Illinois: Moving Toward NP Independence

Who can prescribe:

• Psychiatrists: Full authority
• PMHNPs: Can obtain Full Practice Authority after 4,000 hours of clinical practice + 250 hours additional training. Until then, need Written Collaborative Agreement with physician who delegates prescriptive authority. After FPA, can prescribe stimulants independently (no physician consultation requirement for psych meds).

Telehealth prescribing: Illinois strongly supports telehealth with mandated payment parity. No state-specific controlled substance restrictions.

Key requirements:

• NPs need mid-level controlled substance license plus DEA number
• E-prescribing required for all controlled substances since January 2023
• Collaborative agreements must include monthly case discussions and chart review (pre-FPA)

Market conditions:

• Psychiatrist density: ~1 per 5,849 residents (slightly below average)
• Strong provider concentration in Chicago metro; downstate Illinois has significant shortages
• Growing number of independent PMHNPs with FPA by 2026
• Good insurance coverage, telehealth-friendly environment

The trend: Illinois is transitioning to more NP autonomy. If you’re an experienced PMHNP, this is one of the more favorable regulatory environments. Newer NPs still need MD collaboration but have a clear path to independence.

The Economics: What ADHD Telehealth Actually Pays

Insurance reimbursement is strong. Telehealth parity is nearly universal across states now — you get paid the same for a video visit as you would for in-office medication management.

Typical rates (2026 Medicare fee schedule):

• Initial evaluation (90792): $188-$202
• 15-minute med check (99213): ~$90
• 25-minute visit (99214): ~$125-$136

Commercial insurance usually pays 10-30% higher than Medicare. Medicaid pays substantially less (roughly half Medicare rates or $40-$65 for a med check), but telehealth helps balance a mixed payor panel.

The psychiatrist advantage: MDs are reimbursed at the highest levels for psychiatric services compared to other provider types. Some insurers pay NPs at 85% of physician rates when billing under their own NPI.

Volume economics: A psychiatrist doing four 15-minute med checks per hour via telehealth (standard ADHD follow-up workflow) generates approximately:

• $360/hour with Medicare patients
• $400-$500+/hour with commercial insurance
• Less overhead than office-based practice (no rent, minimal staff)

The patient acquisition question: This is where telehealth platforms make their pitch. Building your own ADHD practice through traditional marketing is expensive and slow:

• SEO takes 6-12 months of consistent investment before generating meaningful patient flow
• Google Ads for mental health keywords cost $15-40+ per click, and most clicks don’t convert to booked patients
• Realistic cost per booked patient through DIY marketing: $200-$500+ when you factor in agency fees, ad spend, staff time to handle leads, no-show rates, and failed campaigns
• Directory listings (Psychology Today, Zocdoc) charge monthly subscription fees PLUS per-booking fees, and you compete with hundreds of other providers on the same page

Most solo providers don’t have the expertise, budget, or patience for this. You end up spending $3,000-5,000/month on marketing with uncertain results — that’s the equivalent of 30-50 patient visits just to break even on marketing costs.

Platform model economics: Services like Klarity use a pay-per-appointment model where providers pay a standard listing fee per new patient lead. The value proposition:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients

The ROI comparison: Instead of gambling $5,000/month on marketing that might not work, you pay only when a qualified patient books with you. That’s guaranteed ROI vs. risk.

Reality check: Acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+ when you account for ALL costs. A platform that charges a per-appointment fee in that range but removes all the risk and infrastructure burden is economically rational — especially for providers who want to focus on clinical care, not marketing.

Clinical Workflow: How ADHD Medication Management Actually Works via Telehealth

Initial evaluation (45-60 minutes):

• Comprehensive psychiatric interview via video
• DSM-5 diagnostic criteria assessment
• Rating scales (ADHD-RS, ASRS for adults) — can be completed electronically before visit
• Collateral information when appropriate (teacher reports for kids, partner observations for adults)
• Screen for comorbidities (anxiety, depression, substance use)
• Document previous treatment history, medication trials
• Assess for contraindications (cardiac history, active substance abuse, psychosis)

What you can’t do through a screen: Physical exam elements like vitals. Work-around: Ask patients to get blood pressure checked at pharmacy or use home monitor. Some providers coordinate baseline EKG for older patients or those with cardiac concerns (not routinely required for stimulants, but defensible practice).

Prescribing workflow:

• E-prescribe through DEA-compliant platform (required in most states)
• Check state prescription drug monitoring program (PDMP) — mandatory in many states before writing controlled substances
• Document justification for stimulant therapy, informed consent discussion covering risks
• Most providers start with once-daily long-acting formulations (less abuse potential than immediate-release)

Follow-up visits (10-15 minutes monthly):

• Symptom monitoring (work/school performance, attention, impulsivity)
• Side effects check (appetite, sleep, anxiety, cardiovascular)
• Adherence assessment
• PDMP review (every 90 days minimum in most states)
• Dose adjustments as needed

Refill logistics: Schedule II drugs can’t have refills — each month needs a new prescription. Most platforms set up recurring monthly appointments to ensure continuity and compliance.

Red flags to watch for:

• Requests for immediate-release formulations or dose escalation without clear rationale
• ‘Lost medication’ stories that happen repeatedly
• Resistance to monitoring or urine drug screens when clinically indicated
• Patients who miss follow-ups then request early refills

Documentation is your protection: The states that have cracked down on inappropriate telehealth stimulant prescribing are looking at providers who did 10-minute video chats and wrote scripts with minimal evaluation. Comprehensive documentation — thorough initial assessment, regular monitoring, clinical justification for treatment decisions — is both good patient care and legal protection.

What Could Change: The Regulatory Uncertainty

Federal level: Congress might pass permanent telehealth controlled substance rules, the DEA might finalize the ‘special registration’ pathway, or we could revert to requiring in-person exams for new patients. As of February 2026, we don’t know which way it goes.

State level: Several trends to watch:

• More states moving toward NP full practice authority (though strong opposition in some states)
• Ongoing scrutiny of telehealth prescribing practices after high-profile cases of abuse
• Potential state-specific rules on ‘prescriber-patient relationship’ that could require video for controlled substances (prohibiting phone-only)

What providers should do:

• Get licensed in multiple states if you’re practicing telehealth (interstate compacts help for MDs but not as much for NPs)
• Build relationships with local providers who could do in-person exams if federal rules change
• Maintain competency in non-stimulant ADHD treatment options (atomoxetine, guanfacine, bupropion) as backup
• Keep detailed documentation that demonstrates you’re practicing to the standard of care

The Platform Decision: When Joining a Service Makes Sense

If you’re a psychiatrist:

• Texas or Florida: Your MD license makes you essential because NPs can’t prescribe stimulants independently. Platforms need MDs in these states.
• High-supply states (NY, CA): Competition is fierce, but patient demand is enormous. A platform that handles patient acquisition and infrastructure removes the barrier to building volume quickly.
• Rural licensure: If you’re licensed in states with provider shortages, your capacity to see patients is valuable — platforms will actively recruit you.

If you’re a PMHNP:

• Restricted states: You need a collaborating psychiatrist. Some platforms arrange this for you. Otherwise you’re limited to non-stimulant management.
• Independent practice states (post-experience): Once you have 3,600+ hours (NY) or FPA (IL), you can operate equivalently to an MD. Platforms offer the same patient acquisition value without limiting your scope.

The economics make sense when:

• You want to avoid the $3,000-5,000/month upfront cost of building your own practice
• You don’t have marketing expertise or time to manage SEO, Google Ads, and lead conversion
• You want predictable patient flow without gambling on whether your marketing will work
• You value built-in infrastructure (EMR, telehealth platform, billing) over building everything from scratch

Platform model isn’t right when:

• You already have an established practice with steady patient flow
• You prefer full control over patient selection and pricing
• You want to build equity in your own brand rather than working through another company’s platform

Questions to ask any platform:

• What’s the actual per-appointment fee structure and are there hidden costs?
• How are patients qualified before they’re matched to me?
• What states do you operate in and do you help with licensing/collaboration agreements?
• What percentage of patients have insurance vs cash-pay?
• What’s your policy on patient selection — can I decline patients who don’t fit my practice?
• What happens if federal controlled substance rules change?

Practical Takeaways: What To Do Next

If you’re already doing telehealth and want to add ADHD:

1. Check your state’s NP vs MD rules — this determines whether you can prescribe stimulants independently or need a collaborator
2. Verify your DEA registration is current and includes your telehealth practice address
3. Set up PDMP access for every state you’re licensed in (required in most states before writing controlled substances)
4. Implement standardized evaluation protocols — use validated rating scales, document thoroughly, get collateral information
5. Review your malpractice coverage to ensure telehealth is covered, particularly for controlled substance prescribing

If you’re considering joining a platform:

1. Get licensed in high-demand states where your credential type has full scope (MDs: anywhere; NPs: focus on independent practice states if possible)
2. Calculate the real economics — compare platform per-appointment fees against the full cost of DIY patient acquisition
3. Understand the patient volume model — how many patients can you realistically see per week doing monthly med checks?
4. Ask about liability and compliance support — who helps if there’s a regulatory issue or patient complaint?

If you’re in a restricted state as a PMHNP:

1. Find a collaborating psychiatrist who’s comfortable with remote supervision (some platforms help arrange this)
2. Get clear on what you can do — often you can do everything except write the actual stimulant prescription
3. Consider getting licensed in an independent practice state in addition to your home state to expand opportunities

If you’re a psychiatrist in a shortage state (TX, FL):

1. You’re in demand — both for direct patient care and as a collaborator for NPs
2. Document meticulously — these states have seen regulatory scrutiny of telehealth prescribing
3. Consider the leverage — you can either see patients directly or collaborate with multiple NPs to expand reach (within state limits on collaboration)

The Bottom Line

Yes, psychiatrists can prescribe ADHD medications via telehealth in 2026 — but the details matter enormously depending on whether you’re an MD or PMHNP and which state you’re practicing in.

The federal telehealth allowance remains in effect through 2025 (extended multiple times), meaning you can initiate stimulant treatment through video visits without an in-person exam first. But this could change, so have a backup plan.

State scope-of-practice laws are the real differentiator. MDs have full authority everywhere. PMHNPs range from nearly-equivalent authority (NY, IL after experience) to severely restricted (TX, where you can’t prescribe outpatient stimulants at all).

The demand is real and growing. Adult ADHD diagnoses surged during the pandemic and haven’t declined. Medication shortages (Adderall, Vyvanse) persist. Wait times for appointments are measured in months in many areas. Telehealth is how many patients access care now.

The economics favor providers who can acquire patients cost-effectively. Building your own practice through DIY marketing costs $200-500+ per acquired patient when you factor in all costs — money you spend before seeing a single patient. Platforms that use pay-per-appointment models remove that risk entirely.

Documentation and clinical judgment are your protection. The cases that drew regulatory attention involved minimal evaluations and inappropriate prescribing. If you conduct thorough assessments, monitor patients regularly, check prescription monitoring programs, and document everything — you’re practicing good medicine and protecting your license.

The opportunity is significant. Whether you join a platform or build independently, ADHD medication management via telehealth addresses a massive unmet need — if you understand the rules where you practice and play by them.

State Requirements Summary Table

Sources and Verification

All information in this guide is based on current state statutes, regulatory guidance, and federal policy as of February 2026. Here are the key sources used:

Official State Laws & Regulations

• Florida Statutes §456.47 (Telehealth controlled substances exceptions) — Current through 2023 session
• Florida Statutes §464.012 (APRN prescribing rules, 7-day limit and psychiatric nurse exception) — 2025 edition
• Texas SB 2527 Bill Analysis (88th Legislature, 2023) — Legislative analysis of telehealth prescribing concerns
• Pennsylvania Code 49 Pa. Code §21.284 (CRNP prescribing parameters) — Current regulations
• Illinois Nurse Practice Act 225 ILCS 65 (APRN Full Practice Authority) — Amended 2017, effective 2018

Federal & Industry Sources

• Axios Healthcare — ‘COVID-era telehealth prescribing extended again’ (Nov 18, 2024) — Reports DEA/HHS extension through end of 2025
• Axios — ‘Telehealth prescribing mess could reach Congress’ (Sept 18, 2024) — Analysis of federal policy uncertainty
• Associated Press — ‘More adults sought help for ADHD during pandemic’ (Jan 10, 2024) — Data on prescription surge and shortages
• RxAgent — ‘NP Prescriptive Authority by State (2026 Guide)’ (Updated Dec 28, 2025) — Comprehensive state-by-state NP scope compilation

Healthcare Policy & Market Data

• Center for Connected Health Policy (CCHP) — State telehealth law summaries (Updated Jan 19, 2026) — Detailed Texas and other state rules
• Healing Psychiatry Florida — ‘Psychiatrist Shortage by State – 2026 Report’ (Jan 15, 2026) — Psychiatrist per capita data by state
• Therathink — ‘Insurance Reimbursement Rates for Psychiatrists [2026]’ (Updated 2026) — CPT code payment data
• BehaveHealth — ‘Mental Health Reimbursement Trends’ (2024) — Commentary on telehealth parity status

All sources have been cross-verified for accuracy. Official statutes and regulations were prioritized for legal requirements. News and industry sources provide context on trends, market conditions, and policy developments. No information was included that couldn’t be verified through multiple authoritative sources.

Reliability assessment: Primary sources (state statutes, federal regulations) rated highest reliability. Industry compilations (RxAgent, CCHP) rated high for comprehensiveness but cross-checked against primary sources. Market data (shortage statistics, reimbursement rates) rated medium-high reliability based on data transparency and source credibility.

Last verification date: February 2026. Regulatory landscape for telehealth controlled substance prescribing remains fluid pending federal action later in 2026.

Source:

• https://www.axios.com/2024/09/18/telehealth-services-controlled-substances-congress#:~:text=Why%20it%20matters%3A%20Pandemic,end%20of%20this%20year%20after
• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20and,the%20third%20temporary%20extension%20of
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.flsenate.gov/Laws/Statutes/2023/456.47#:~:text=1,disorder
• https://rxagent.co/blog/np-prescribing-authority#:~:text=OK%20%20,day%20%28ongoing%29%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=TN%20%20,NP%3A%20Independent%20%5B3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=match%20at%20L210%20NY%20,terminal%20illness%2C%20MD%20initiation
• https://rxagent.co/blog/np-prescribing-authority#:~:text=ID%20%20,3
• https://rxagent.co/blog/np-prescribing-authority#:~:text=FL%20%20,NP%3A%20Independent%20%5B3
• https://www.leg.state.fl.us/STATUTeS/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=also%20limit%20the%20prescribing%20of,shall%20adopt%20by%20rule%20the